RxDoctor Payments Data

Abdullahi Musa Adamu, MD

Neurology · Minot, NDNPI 1437788494

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.9% of the total. Reporting peaked in 2024 at $911 and has fallen 95.0% since, to $45 in 2025.

$973in general payments, 2019–2025

Across 42 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$281
  • Livanova USA, Inc.$155
  • UCB, Inc.$95
  • EMD Serono, Inc.$58
  • Sumitomo Pharma America, Inc.$44
  • Novartis$38
  • plus $301 from 11 others

What the payments were for

  • Food & beverage$973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 65th percentile of 39 neurology providers in North Dakota.

See all neurology providers in North Dakota

Medicare billing

Part B allowed, 2024
$6,214
Medicare patients
47
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$136,746
Emgality PenGalcanezumab-Gnlm22$19,807
Gabapentin54$1,361
Levetiracetam31$1,036
Divalproex Sodium ErDivalproex Sodium20$748
Carbidopa-Levodopa ErCarbidopa/Levodopa13$715
Amitriptyline Hcl19$313
Memantine Hcl20$208
Atorvastatin Calcium21$207
Donepezil Hcl16$176
Clonazepam12$82
Topiramate14$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$28$8214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 39 neurology providers in North Dakota.

Other neurology in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →